Meta-analysis of studies including nonsmall cell lung cancer (NSCLC) of any stage, with their characteristics
| First author [ref. no.] | Method | QS % | Patients n | p53+ % | HR | 95% CI |
| Fujino 32 | IHC-;DO-;7 | 70 | 91 | 58 | 1.71 | 1.05–2.78 |
| Greatens 36 | PCR-;SSCP | 55 | 101 | 40 | 1.81 | 1.00–3.26 |
| Hayakawa 41 | IHC-;DO-;7 | 58 | 36 | 69 | 1.55 | 0.51–4.71 |
| Kim 10 | IHC | 79 | 238 | 18 | 1.00 | 0.55–1.82 |
| Levesque 59 | ELISA | 63 | 71 | 48 | 2.47 | 1.03–5.92 |
| Mitsudomi 55 | PCR-;SSCP | 53 | 120 | 43 | 1.92 | 1.17–3.15 |
| Murakami 70 | PCR-;DGGE | 63 | 54 | 39 | 1.12 | 0.60–2.08 |
| Ohsaki 74 | IHC-;DO-;7 | 54 | 99 | 44 | 1.47 | 0.91–2.37 |
| Quantin 78 | IHC-;1801 | 71 | 89 | 52 | 0.85 | 0.46–1.60 |
| Tagawa 83 | PCR-;SSCP | 24 | 67 | 34 | 1.44 | 0.59–3.52 |
| Xu [92] | IHC | 57 | 66 | 56 | 1.30 | 0.79–2.13 |
| Overall | 58 | 1032 | 44 | 1.44 | 1.20–1.72 | |
QS: quality score
p53+: presence of an abnormality of p53
HR: hazard ratio
CI: confidence interval
IHC-;DO-;7: immunohistochemistry with monoclonal antibody DO-;7
PCR: polymerase chain reaction
SSCP: single-strand conformation polymorphism method
DGGE: denaturing gradient gel electrophoresis
IHC-;1801: immunohistochemistry with monoclonal antibody 1801
IHC: immunohistochemistry with antibodies other than DO-;7 or 1801
ELISA: enzyme-linked immunosorbent assay technique
Group of NSCLC all stages, n=11
Chi-;squared statistic for heterogeneity = 8.70, 10 degrees of freedom, p=0.56